In patients with chronic kidney disease (CKD), SGLT2 inhibitors have been associated with alterations in bone and mineral metabolism, including increased serum phosphate, fibroblast growth factor-23 (FGF-23), and parathyroid hormone (PTH) levels, along with decreased 1,25-dihydroxyvitamin D levels. The gene discussed is FGF23; the disease is chronic kidney disease.